Q-omics provides the consensus-scored LINC01222 profile across patient tissues and cancer cell-line models. LINC01222 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01222 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, LINC01222 RNA expression shows 10,075 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where LINC01222 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01222 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01222 survival associations across molecular data types. LINC01222 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01222 RNA expression–survival associations across cancer types. High LINC01222 expression shows unfavorable associations in KIRC, UCEC, BRCA, COAD and SARC, but favorable associations in LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .013). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01222 RNA expression.
This table summarizes LINC01222 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01222. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01222 shows higher tumor expression in KIRC. The KIRC box plot shows higher LINC01222 RNA expression in tumor versus normal tissue (log2 FC = +0.004, t-test p = .010).
This table shows molecular features associated with LINC01222 in patient tissues and cancer cell lines. In patient samples, LINC01222 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
